Q3 2022 Results slide image

Q3 2022 Results

Company overview Financial performance Cardiovascular Financial review 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Immunology Neuroscience Oncology Immunology References Abbreviations Other 51 Investor Relations | Q3 2022 Results NOVARTIS | Reimagining Medicine
View entire presentation